Vedana secured $46m to develop anti-PACAP and bispecific PACAP/CGRP antibodies that may rival Amgen’s Aimovig migraine therapy. Eli Lilly posted 56% revenue growth with $12.8bn from Mounjaro and Zepbound sales, prioritizing new drug launches and acquisitions over GLP-1 manufacturing expansion.
Vedana Therapeutics completed a $46m Series A financing co-led by Canaan Partners and Westlake BioPartners to advance its subcutaneous migraine portfolio. The proceeds will fund development of a long-acting anti-PACAP antibody and a bispecific agent targeting both PACAP and CGRP.
Vedana’s focus on PACAP inhibition represents a strategic move beyond existing CGRP therapies such as Aimovig. Since two-thirds of patients fail to achieve optimal control with first-generation CGRP inhibitors, these novel candidates could capture unmet demand.
Eli Lilly reported a 56% revenue increase after Mounjaro and Zepbound generated $12.8bn in global sales. The company is shifting resources from GLP-1 manufacturing scale-up to new product launches and acquisitions, reflecting confidence in supply stability.
The migraine treatment market is projected to grow from $9.2bn in 2023 to $16.4bn by 2033 across the seven major markets. The entry of PACAP-targeting assets and intensified M&A activity underscore escalating competition for market share.
